Drug Trial Radar · NCT07813884
Exploratory Evaluation of the BiP Inhibitor BPR001-615 in Primary Cells and the Diagnostic Value of Circulating BiP in Colorectal Adenocarcinomas
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Oct 1, 2027
Study completion Oct 1, 2027
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de NiceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Colorectal cancer is one of the most common cancers worldwide. Although surgery and drug treatments have improved, some colorectal cancers may continue to grow or become resistant to treatment. Researchers are therefore looking for new biological targets that could help develop future therapies. BiP, also known as GRP78, is a protein normally present inside cells. It helps cells manage stress and maintain normal protein function. Cancer cells are often exposed to stressful conditions, such as low oxygen levels and limited nutrients. To survive in this environment, they may produce increased amounts of BiP. High BiP activity may help cancer cells avoid cell death, continue to grow, and become more resistant to treatment. BPR001-615 is an experimental compound developed to block the activity of BiP. The main hypothesis of the COLBiP study is that inhibition of BiP by BPR001-615 will reduce the viability and growth of human colorectal cancer cells in a dose-dependent manner. The compound will only be tested in the laboratory on tumor cells obtained during surgery. It will not be administered to participants, and the results of the laboratory tests will not be used to guide their treatment. COLBiP is a prospective, single-center, exploratory pilot study conducted at Nice University Hospital. The study will include 15 adult patients undergoing planned surgical removal of a confirmed colorectal adenocarcinoma. During the participant's usual hospital care, a 5 mL blood sample will be collected, preferably at the same time as routine blood sampling or placement of an intravenous line. After the tumor has been surgically removed, a small fresh tissue fragment will be collected from the surgical specimen. This sampling will not interfere with the tissue required for routine diagnosis, which will remain the priority. The tumor fragment will be transported to the C3M laboratory, where researchers will isolate the tumor cells and grow them in primary cell culture. These cells will then be exposed to increasing concentrations of BPR001-615. The effect of the compound will be evaluated by measuring cell viability and growth using two complementary laboratory methods: the WST-1 assay and cell counting with trypan blue exclusion. The researchers will establish a dose-response curve and, when possible, estimate the concentration of BPR001-615 required to reduce cell viability by 50%. In parallel, the amount of circulating BiP in the blood will be measured using an ELISA laboratory test. BiP expression within the tumor tissue will also be evaluated using immunohistochemistry. The study will explore whether circulating BiP levels, tumor BiP expression, and the response of the tumor cells to BPR001-615 are associated with one another. Researchers will also examine whether BiP levels are associated with routinely collected tumor characteristics, including tumor stage and histological features. There is no expected direct medical benefit for participants, and participation will not change their usual diagnosis, surgery, or treatment. The procedures specific to the study use blood and tumor tissue collected during routine care, and the additional risk is expected to be minimal. This pilot study aims to provide early evidence about the activity of BPR001-615 in human colorectal cancer cells and to assess whether BiP could be useful as a biomarker in future studies of BiP-targeted treatments.
Conditions
- Colorectal Adenocarcinoma
Interventions
BPR001-615Biological
BPR001-615 is an experimental small-molecule inhibitor of the chaperone protein BiP/GRP78. It is not administered to study participants. Fresh tumor cells isolated from colorectal adenocarcinoma surgical specimens are cultured ex vivo and exposed to several concentrations of BPR001-615 to generate a dose-response curve. The concentration range will be centered around approximately 1 µM, based on previous colorectal cancer cell-line experiments. Cytotoxic activity is assessed by comparing treated cultures with untreated control cultures using the WST-1 viability assay and trypan blue exclusion cell counting. When data permit, an ex vivo IC50 will be estimated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ex vivo viability of primary colorectal cancer cells after BPR001-615 exposureTime frame: Day 5 of ex vivo primary cell culture, after exposure to BPR001-615.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU de Nice
Nice, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.